Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Sepsis Outcome Programme (AESOP) Annual Report 2017
DOI:
https://doi.org/10.33321/cdi.2019.43.42Keywords:
Australian Group on Antimicrobial Resistance (AGAR), antimicrobial resistance surveillance, Enterococcus faecium, Enterococcus faecalis, Vancomycin Resistant Enterococci (VRE), BacteraemiaAbstract
From 1 January to 31 December 2017, 36 institutions around Australia participated in the Australian Enterococcal Sepsis Outcome Programme (AESOP). The aim of AESOP 2017 was to determine the proportion of enterococcal bacteraemia isolates in Australia that were antimicrobial resistant, and to characterise the molecular epidemiology of the E. faecium isolates. Of the 1,137 unique episodes of bacteraemia investigated, 95.2% were caused by either E. faecalis (52.9%) or E. faecium (42.3%). Ampicillin resistance was not detected in E. faecalis but in 89.6% of E. faecium. Vancomycin non-susceptibility was reported in 0.3% and 47.0% of E. faecalis and E. faecium respectively. Overall 50.9% of E. faecium harboured vanA or vanB genes. For the vanA/B positive E. faecium isolates, 49.6% harboured vanB genes and 49.2% vanA genes; 1.2% harboured vanA and vanB genes. The percentage of E. faecium bacteraemia isolates resistant to vancomycin in Australia is significantly higher than that seen in most European countries. E. faecium consisted of 76 multilocus sequence types (STs) of which 77% of isolates were classified into nine major STs containing ten or more isolates. All major STs belong to clonal cluster (CC) 17, a major hospital-adapted polyclonal E. faecium cluster. Seven of the nine predominant STs (ST80, ST1421, ST17, ST296, ST555, ST203 and ST18) were found across most regions of Australia. The most predominant clone was ST17 which was identified in all regions except the Australian Capital Territory, the Northern Territory and Tasmania. Overall 60.7% of isolates belonging to the nine predominant STs harboured vanA or vanB genes. The AESOP 2017 has shown enterococcal bacteraemias in Australia are frequently caused by polyclonal ampicillin-resistant high-level gentamicin resistant vanA or vanB E. faecium which have limited treatment options.
Downloads
References
Pinholt M, Ostergaard C, Arpi M,Bruun NE, Schønheyder HC, Gradel KO et al. Incidence, clinical characteristics and 30-day mortality of enterococcal bacteraemia in Denmark 2006–2009: a population-based cohort study. Clin Microbiol Infect. 2014;20(2):145–51.
Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis. 2007;58(2):163–70.
Murray BE. The life and times of the Enterococcus. Clin Microbiol Rev. 1990;3(1):46–65.
Simonsen GS, Småbrekke L, Monnet DL, Sørensen TL, Møller JK, Kristinsson KG et al. Prevalence of resistance to ampicillin, gentamicin and vancomycin in Enterococcus faecalis and Enterococcus faecium isolates from clinical specimens and use of antimicrobials in five Nordic hospitals. J Antimicrob Chemother. 2003;51(2):323–31.
Treitman AN, Yarnold PR, Warren J, Noskin GA. Emerging incidence of Enterococcus faecium among hospital isolates (1993 to 2002). J Clin Microbiol. 2005;43(1):462–3.
Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1–12.
Christiansen KJ, Turnidge JD, Bell JM, George NM, Pearson JC; Australian Group on Antimicrobial Resistance. Prevalence of antimicrobial resistance in Enterococcus isolates in Australia, 2005: report from the Australian Group on Antimicrobial Resistance. Commun Dis Intell Q Rep. 2007;31(4):392–7.
Coombs GW, Daley D, Pearson JC, Ingram PR. A change in the molecular epidemiology of vancomycin resistant enterococci in Western Australia. Pathology. 2014;46(1):73–5.
Coombs GW, Pearson JC, Daley DA et al. Molecular epidemiology of enterococcal bacteremia in Australia. J Clin Microbiol. 2014;52(3):897–905.
Clinical and Laboratory Standards Institute (CLSI). M100-S24 Performance standards for antimicrobial susceptibility testing; Twenty-fourth informational supplement. Villanova, PA, USA, 2014.
European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints – bacteria v 5.0. 2015. Available from: http://www.eucast.org/ast_of_bacteria/previous_versions_of_documents/
Seemann T, Goncalves da Silva A, Bulach DM, Schultz MB, Kwong JC, Howden BP. Nullarbor. San Francisco; Github. [Accessed: 03 Jun 2016]. Available from: https://github.com/tseemann/nullarbor
European Centre for Disease Prevention and Control (ECDC). Surveillance of antimicrobial resistance in Europe 2017. [Internet.] European Centre for Disease Prevention and Control; 2018. Available from: https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2017
Coombs GW, Pearson JC, Daley DA, Le TT, Robinson JO, Gottlieb T et al. Australian Enterococcal Sepsis Outcome Programme annual report, 2013. Commun Dis Intell Q Rep. 2014;38(4):E320–6.
Coombs GW, Daley DA, Thin Lee Y, Pang S, Pearson JC, Robinson JO et al. Australian Group on Antimicrobial Resistance Australian Enterococcal Sepsis Outcome Programme annual report, 2014.Commun Dis Intell Q Rep. 2016;40(2):E236–43.
Coombs GW, Daley DA, Lee YT, Pang S, Bell JM, Turnidge JD for the Australian Group on Antimicrobial Resistance. Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Sepsis Outcome Programme (AESOP) Annual Report 2015. Commun Dis Intell(2018). 2018;42. pii: S2209-6051(18)00015-5.
Coombs GW, Daley DA, Lee YT, Pang S for the Australian Group on Antimicrobial Resistance. Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Sepsis Outcome Programme (AESOP) Annual Report 2016. Commun Dis Intell(2018). 2018;42. pii: S2209-6051(18)00020-9.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2019 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
